Joanna Yuet-Ling Tung1, Kara Boodhansingh1, Charles A Stanley1,2, Diva D De León1,3. 1. Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Dominant inactivating mutations in HNF1A and HNF4A have been described to cause hyperinsulinism (HI) before evolving to diabetes. However, information available in the literature regarding the clinical phenotype is limited. OBJECTIVE: To report the prevalence of HNF1A and HNF4A mutations in a large cohort of children with HI, and to describe their genotypes and phenotypes. DESIGN: Retrospective descriptive study. METHODS: Medical records were reviewed to extract clinical information. Mutation analysis was carried out for 8 genes associated with HI (ABCC8, KCNJ11, GLUD1, GCK, HADH, HNF4A, HNF1A, and UCP2). RESULTS: HNF1A and HNF4A mutations were identified in 5.9% (12 out of 204; HNF1A = 7, HNF4A = 5) of diazoxide-responsive HI probands. The clinical phenotypes were extremely variable. Two children showed evidence of ketone production during hypoglycemia, a biochemical profile atypical for hyperinsulinism. At the time of analysis, diazoxide was discontinued in 5 children at a median age of 6.8 years. None had developed diabetes mellitus at a median age of 7.0 years. CONCLUSIONS: Given the heterogeneous clinical phenotypes of HNF1A- and HNF4A-HI, all children with transient, diazoxide-responsive HI without clear history of perinatal stress, should be screened for HNF1A and HNF4A mutations as it predicts the clinical course and affects the subsequent management plan.
BACKGROUND: Dominant inactivating mutations in HNF1A and HNF4A have been described to cause hyperinsulinism (HI) before evolving to diabetes. However, information available in the literature regarding the clinical phenotype is limited. OBJECTIVE: To report the prevalence of HNF1A and HNF4A mutations in a large cohort of children with HI, and to describe their genotypes and phenotypes. DESIGN: Retrospective descriptive study. METHODS: Medical records were reviewed to extract clinical information. Mutation analysis was carried out for 8 genes associated with HI (ABCC8, KCNJ11, GLUD1, GCK, HADH, HNF4A, HNF1A, and UCP2). RESULTS: HNF1A and HNF4A mutations were identified in 5.9% (12 out of 204; HNF1A = 7, HNF4A = 5) of diazoxide-responsive HI probands. The clinical phenotypes were extremely variable. Two children showed evidence of ketone production during hypoglycemia, a biochemical profile atypical for hyperinsulinism. At the time of analysis, diazoxide was discontinued in 5 children at a median age of 6.8 years. None had developed diabetes mellitus at a median age of 7.0 years. CONCLUSIONS: Given the heterogeneous clinical phenotypes of HNF1A- and HNF4A-HI, all children with transient, diazoxide-responsive HI without clear history of perinatal stress, should be screened for HNF1A and HNF4A mutations as it predicts the clinical course and affects the subsequent management plan.
Authors: S E Flanagan; R R Kapoor; G Mali; D Cody; N Murphy; B Schwahn; T Siahanidou; I Banerjee; T Akcay; O Rubio-Cabezas; J P H Shield; K Hussain; S Ellard Journal: Eur J Endocrinol Date: 2010-02-17 Impact factor: 6.664
Authors: Lorna W Harries; Jonathan M Locke; Beverley Shields; Neil A Hanley; Karen Piper Hanley; Anna Steele; Pål R Njølstad; Sian Ellard; Andrew T Hattersley Journal: Diabetes Date: 2008-03-20 Impact factor: 9.461
Authors: Kevin Colclough; Christine Bellanne-Chantelot; Cecile Saint-Martin; Sarah E Flanagan; Sian Ellard Journal: Hum Mutat Date: 2013-04-02 Impact factor: 4.878
Authors: Ritika R Kapoor; Jonathan Locke; Kevin Colclough; Jerry Wales; Jennifer J Conn; Andrew T Hattersley; Sian Ellard; Khalid Hussain Journal: Diabetes Date: 2008-02-11 Impact factor: 9.461
Authors: Alexander J Hamilton; Coralie Bingham; Timothy J McDonald; Paul R Cook; Richard C Caswell; Michael N Weedon; Richard A Oram; Beverley M Shields; Maggie Shepherd; Carol D Inward; Julian P Hamilton-Shield; Jürgen Kohlhase; Sian Ellard; Andrew T Hattersley Journal: J Med Genet Date: 2013-11-27 Impact factor: 6.318
Authors: Kara E Boodhansingh; Zhongying Yang; Changhong Li; Pan Chen; Katherine Lord; Susan A Becker; Lisa J States; N Scott Adzick; Tricia Bhatti; Show-Ling Shyng; Arupa Ganguly; Charles A Stanley; Diva D De Leon Journal: Eur J Endocrinol Date: 2022-06-27 Impact factor: 6.558
Authors: Kara E Boodhansingh; Balamurugan Kandasamy; Lauren Mitteer; Stephanie Givler; Diva D De Leon; Show-Ling Shyng; Arupa Ganguly; Charles A Stanley Journal: Am J Med Genet A Date: 2019-08-28 Impact factor: 2.802
Authors: Sara Jane Cromer; Aluma Chovel Sella; Emily Rosenberg; Kevin Scully; Marie McDonnell; Ana Paula Abreu; Michelle Weil; Sarah N Bernstein; Maryanne Quinn; Camille Powe; Deborah M Mitchell; Miriam S Udler Journal: AACE Clin Case Rep Date: 2022-08-08